Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

23.31 

1.05 4.7%

as of Mar 26 '19

52 Week Range:

20.88 27.87


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Kissei Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in Japan. It offers Urief and OD tablets for the treatment of dysuria; Glufast and Glubes tablets for diabetes; Epoetin Alfa BS injection for the treatment of renal anemia; P-TOL chewable tablets for treating hyperphosphatemia in patients on dialysis; Mitiglinide for treating Type 2 diabetes mellitus; and RECTABUL, a rectal foam product for the treatment of ulcerative colitis. The company's product pipeline includes KPS-0373 that is in Phase III clinical trials for spinocerebellar ataxia; AJM300, which is in Phase III clinical trials for ulcerative colitis; YS110, which is in Phase I/II clinical trials for Malignant mesothelioma; and JR-131 that is in NDA preparation for renal anemia. It is also developing KLH-2109, which is in Phase II clinical trials for treating endometriosis and uterine fibroids; KDT-3594 that is in Phase I clinical trials for Parkinson's disease; MR13A9 that is in Phase II clinical trials for uremic pruritus in dialysis patients; and CCX168, which is in Phase I clinical trials for the treatment of anti-neutrophil cytoplasmic auto-antibody associated vasculitis. In addition, the company is developing Bedoradrine that is in Phase I clinical trials for the treatment of acute exacerbation of asthma; and Phase II clinical trials for the treatment of COPD, as well as provides information solution and construction subcontracting services. Additionally, it develops and sells protein controlled and energy supply foods. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. Kissei Pharmaceutical Co., Ltd. was founded in 1946 and is headquartered in Matsumoto, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Equity (BVPS) 13.88
16.59
18.33
19.41
21.37
20.51
19.68
22.61
26.04
27.39
28.69
growth rate 19.5% 10.5% 5.9% 10.1% -4.0% -4.1% 14.9% 15.2% 5.2% 4.8%
Earnings BIT 12,301.00
8,335.00
10,276.00
8,491.00
9,888.00
growth rate -32.2% 23.3% -17.4% 16.5%
Avg.PE 20.24
16.14
13.02
growth rate -20.3% -19.3%
ROA 1.48
1.42
3.04
2.73
3.28
3.30
5.47
4.05
4.36
4.06
4.52
growth rate -4.1% 114.1% -10.2% 20.2% 0.6% 65.8% -26.0% 7.7% -6.9% 11.3%
ROE 1.92
1.74
3.61
3.23
3.86
3.89
6.56
4.89
5.30
4.90
5.43
growth rate -9.4% 107.5% -10.5% 19.5% 0.8% 68.6% -25.5% 8.4% -7.6% 10.8%
ROIC 1.65
1.56
3.48
3.12
3.73
3.78
6.38
4.76
5.17
4.79
5.31
growth rate -5.5% 123.1% -10.3% 19.6% 1.3% 68.8% -25.4% 8.6% -7.4% 10.9%
Cur. Ratio 3.23
5.15
5.31
5.65
5.92
5.92
5.64
5.14
5.10
6.21
5.77
growth rate 59.4% 3.1% 6.4% 4.8% 0.0% -4.7% -8.9% -0.8% 21.8% -7.1%
Quick Ratio 2.63
4.16
4.39
4.63
4.90
4.90
4.59
4.02
3.83
4.66
4.39
growth rate 58.2% 5.5% 5.5% 5.8% 0.0% -6.3% -12.4% -4.7% 21.7% -5.8%
Leverage 1.27
1.19
1.19
1.18
1.17
1.19
1.21
1.21
1.22
1.19
1.21
growth rate -6.3% 0.0% -0.8% -0.9% 1.7% 1.7% 0.0% 0.8% -2.5% 1.7%
Balance Sheet Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Acct.Receivable 25,003.00
23,710.00
23,674.00
24,965.00
24,729.00
28,872.00
growth rate -5.2% -0.2% 5.5% -1.0% 16.8%
Acct.Payable 4,882.00
5,390.00
6,045.00
5,829.00
4,849.00
4,894.00
growth rate 10.4% 12.2% -3.6% -16.8% 0.9%
Cur.Assets 92,262.00
100,894.00
97,361.00
100,051.00
97,218.00
100,599.00
growth rate 9.4% -3.5% 2.8% -2.8% 3.5%
Total Assets 160,028.00
172,649.00
181,484.00
193,345.00
186,801.00
213,087.00
growth rate 7.9% 5.1% 6.5% -3.4% 14.1%
Cash 23,937.00
31,266.00
27,241.00
25,666.00
27,109.00
24,371.00
growth rate 30.6% -12.9% -5.8% 5.6% -10.1%
Inventory 11,122.00
12,812.00
14,646.00
17,375.00
16,724.00
15,932.00
growth rate 15.2% 14.3% 18.6% -3.8% -4.7%
Cur.Liabilities 15,577.00
17,879.00
18,934.00
19,608.00
15,656.00
17,448.00
growth rate 14.8% 5.9% 3.6% -20.2% 11.5%
Liabilities 25,245.00
29,829.00
30,765.00
35,222.00
29,019.00
36,996.00
growth rate 18.2% 3.1% 14.5% -17.6% 27.5%
LT Debt 1,525.00
1,409.00
1,463.00
1,488.00
1,656.00
1,876.00
growth rate -7.6% 3.8% 1.7% 11.3% 13.3%
Equity 142,589.00
150,440.00
157,858.00
157,453.00
175,701.00
growth rate 5.5% 4.9% -0.3% 11.6%
Common Shares 58.00
55.00
54.00
54.00
52.00
51.00
51.00
50.00
49.00
49.00
48.00
growth rate -5.2% -1.8% 0.0% -3.7% -1.9% 0.0% -2.0% -2.0% 0.0% -2.0%
Cash Flow Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Capital Expenditures 1,630.00
1,909.00
1,974.00
1,978.00
1,201.00
1,867.00
growth rate 17.1% 3.4% 0.2% -39.3% 55.5%
Cash Dividends 2,007.00
2,110.00
2,103.00
2,201.00
2,270.00
growth rate 5.1% -0.3% 4.7% 3.1%
Cash From OA 9,287.00
11,945.00
6,667.00
5,763.00
6,441.00
8,845.00
growth rate 28.6% -44.2% -13.6% 11.8% 37.3%
FCF per Share 0.38
1.42
1.24
0.42
1.05
0.71
1.14
1.10
0.12
1.20
0.46
growth rate 273.7% -12.7% -66.1% 150.0% -32.4% 60.6% -3.5% -89.1% 900.0% -61.7%
FCF 3,445.00
10,368.00
8,405.00
2,677.00
3,070.00
7,404.00
9,837.00
4,302.00
3,482.00
3,909.00
6,725.00
growth rate 201.0% -18.9% -68.2% 14.7% 141.2% 32.9% -56.3% -19.1% 12.3% 72.0%
Income Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Sales 62,491.00
70,399.00
70,110.00
71,294.00
71,706.00
74,009.00
growth rate 12.7% -0.4% 1.7% 0.6% 3.2%
Op.Income 5,041.00
12,301.00
8,335.00
10,276.00
8,491.00
9,888.00
growth rate 144.0% -32.2% 23.3% -17.4% 16.5%
IBT 13,399.00
10,465.00
11,135.00
10,116.00
11,695.00
growth rate -21.9% 6.4% -9.2% 15.6%
Net Income 5,041.00
9,093.00
7,165.00
8,165.00
7,726.00
9,045.00
growth rate 80.4% -21.2% 14.0% -5.4% 17.1%
EPS 40.16
37.16
80.52
73.78
91.35
97.52
176.67
142.14
166.89
158.74
188.26
growth rate -7.5% 116.7% -8.4% 23.8% 6.8% 81.2% -19.5% 17.4% -4.9% 18.6%
Gross Profit 41,348.00
47,218.00
46,045.00
47,715.00
46,631.00
48,120.00
growth rate 14.2% -2.5% 3.6% -2.3% 3.2%
R&D 11,298.00
14,488.00
14,106.00
13,877.00
14,179.00
growth rate 28.2% -2.6% -1.6% 2.2%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 4,336.00
1,433.00
2,986.00
1,268.00
716.00
growth rate -67.0% 108.4% -57.5% -43.5%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 30,227.00
28,872.00
26,704.00
26,412.00
29,734.00
growth rate -4.5% -7.5% -1.1% 12.6%
Acct.Payable 4,306.00
4,894.00
3,857.00
4,649.00
4,258.00
growth rate 13.7% -21.2% 20.5% -8.4%
Cur.Assets 103,146.00
100,599.00
96,752.00
98,780.00
96,176.00
growth rate -2.5% -3.8% 2.1% -2.6%
Total Assets 211,639.00
213,087.00
211,459.00
222,258.00
201,913.00
growth rate 0.7% -0.8% 5.1% -9.2%
Cash 25,371.00
24,371.00
25,956.00
29,646.00
23,465.00
growth rate -3.9% 6.5% 14.2% -20.9%
Inventory 15,634.00
15,932.00
15,229.00
14,212.00
14,540.00
growth rate 1.9% -4.4% -6.7% 2.3%
Cur.Liabilities 16,420.00
17,448.00
14,222.00
15,160.00
13,465.00
growth rate 6.3% -18.5% 6.6% -11.2%
Liabilities 35,010.00
36,996.00
32,118.00
36,343.00
28,433.00
growth rate 5.7% -13.2% 13.2% -21.8%
LT Debt 1,837.00
1,876.00
1,881.00
1,886.00
1,891.00
growth rate 2.1% 0.3% 0.3% 0.3%
Equity 176,267.00
175,701.00
178,951.00
185,511.00
173,061.00
growth rate -0.3% 1.9% 3.7% -6.7%
Common Shares 24,356.00
24,356.00
24,356.00
24,356.00
24,356.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 20,203.00
17,219.00
17,851.00
17,814.00
19,590.00
growth rate -14.8% 3.7% -0.2% 10.0%
Op.Income 4,336.00
1,433.00
2,986.00
1,268.00
716.00
growth rate -67.0% 108.4% -57.5% -43.5%
IBT 5,064.00
1,162.00
3,554.00
1,088.00
945.00
growth rate -77.1% 205.9% -69.4% -13.1%
Net Income 3,772.00
993.00
2,741.00
596.00
933.00
growth rate -73.7% 176.0% -78.3% 56.5%
Gross Profit 13,176.00
10,684.00
11,459.00
10,700.00
12,929.00
growth rate -18.9% 7.3% -6.6% 20.8%
R&D 14,179.00
14,179.00
growth rate 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

C (50.19)

YOY Growth Grade:

D (33.77)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 14.68 14.97
EPS / Growth 1.56

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 6.9%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 6.9% 6.9% 6.9%
Future PE 0.01 9.52 9.52
Future EPS 3.05 3.05 3.05
Value Price
MOS %
0.01
-100.0%
7.17
-69.2%
7.17
-69.2%
MOS Price 0.00 3.58 3.58
IRT 10.11 10.11 10.11

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.